Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study

The Lancet Respiratory Medicine

Volumn 5, Issue 4, 2017, Pages 282-290

  Andrews, Jason R ^a   Nemes, Elisa ^b   Tameris, Michele ^b   Landry, Bernard S ^c   Mahomed, Hassan ^d   McClain, J Bruce ^c   Fletcher, Helen A ^e   Hanekom, Willem A ^b   Wood, Robin ^f   McShane, Helen ^g   Scriba, Thomas J ^b   Hatherill, Mark ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c AERAS   (United States)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; BCG VACCINE;

ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HUMAN; INCIDENCE; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRESCHOOL CHILD; QUANTIFERON TUBERCULOSIS GOLD IN TUBE TEST; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS; FEMALE; INFANT; INTERFERON GAMMA RELEASE ASSAY; MALE; PROCEDURES; REFERENCE VALUE; SOUTH AFRICA;

COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; INFANT; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; MALE; REFERENCE VALUES; RISK FACTORS; SOUTH AFRICA; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 85012939437     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30060-7     Document Type: Article

References (45)

1. 1 Hawn, TR, Day, TA, Scriba, TJ, et al. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev 78 (2014), 650–671.
2. 2 Graham, SM, Cuevas, LE, Jean-Philippe, P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. Clin Infect Dis 61 (2015), S179–S187.
3. 3 Jenum, S, Selvam, S, Mahelai, D, et al. Influence of age and nutritional status on the performance of the tuberculin skin test and QuantiFERON-TB gold in-tube in young children evaluated for tuberculosis in Southern India. Pediatr Infect Dis J 33 (2014), e260–e269.
4. 4 Lodha, R, Mukherjee, A, Saini, D, et al. Role of the QuantiFERONa-TB Gold In-Tube test in the diagnosis of intrathoracic childhood tuberculosis. Int J Tuberc Lung Dis 17 (2013), 1383–1388.
5. 5 Moyo, S, Isaacs, F, Gelderbloem, S, et al. Tuberculin skin test and QuantiFERON assay in young children investigated for tuberculosis in South Africa. Int J Tuberc Lung Dis 15 (2011), 1176–1181.
6. 6 Schopfer, K, Rieder, HL, Bodmer, T, et al. The sensitivity of an interferon-γ release assay in microbiologically confirmed pediatric tuberculosis. Eur J Pediatr 173 (2014), 331–336.
7. 7 Machingaidze, S, Wiysonge, CS, Gonzalez-Angulo, Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 30 (2011), 694–700.
8. 8 Togun, TO, Egere, U, Gomez, MP, et al. No added value of interferon-γ release to a prediction model for childhood tuberculosis. Eur Respir J 47 (2016), 223–232.
9. 9 Marais, BJ, Gie, RP, Schaaf, HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8 (2004), 392–402.
10. 10 Zar, HJ, Cotton, MF, Strauss, S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ, 334, 2007, 136.
11. 11 Madhi, SA, Nachman, S, Violari, A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 365 (2011), 21–31.
12. 12 WHO. Guidelines on the management of latent tuberculosis infection, 2015, World Health Organization, Geneva.
13. 13 Luabeya, KKA, Tameris, MD, Geldenhuys, HD, et al. Risk of disease after isoniazid preventive therapy for Mycobacterium tuberculosis exposure in young HIV-uninfected children. Pediatr Infect Dis J 34 (2015), 1218–1222.
14. 14 Mahomed, H, Hawkridge, T, Verver, S, et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One, 6, 2011, e17984.
15. 15 Rangaka, MX, Wilkinson, KA, Glynn, JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 45–55.
16. 16 Nenadić, N, Kirin, BK, Letoja, IZ, Plavec, D, Topić, RZ, Dodig, S, Serial interferon-γ release assay in children with latent tuberculosis infection and children with tuberculosis. Pediatr Pulmonol 47 (2012), 401–408.
17. 17 Lienhardt, C, Fielding, K, Hane, AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One, 5, 2010, e10508.
18. 18 Bamford, ARJ, Crook, AM, Clark, JE, et al. Comparison of interferon-gamma release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. Arch Dis Child 95 (2010), 180–186.
19. 19 Zellweger, J-P, Sotgiu, G, Block, M, et al. Risk assessment of tuberculosis in contacts by IFN-γ release assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 191 (2015), 1176–1184.
20. 20 Andrews, JR, Hatherill, M, Mahomed, H, et al. The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 191 (2015), 584–591.
21. 21 Diel, R, Loddenkemper, R, Niemann, S, Meywald-Walter, K, Nienhaus, A, Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 183 (2011), 88–95.
22. 22 Geis, S, Bettge-Weller, G, Goetsch, U, Bellinger, O, Ballmann, G, Hauri, AM, How can we achieve better prevention of progression to tuberculosis among contacts?. Eur Respir J 42 (2013), 1743–1746.
23. 23 Haldar, P, Thuraisingam, H, Patel, H, et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 68 (2013), 240–246.
24. 24 Tameris, MD, Hatherill, M, Landry, BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381 (2013), 1021–1028.
25. 25 Colditz, GA, Berkey, CS, Mosteller, F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis. Pediatrics 96 (1995), 29–35.
26. 26 Ferrara, G, Losi, M, D'Amico, R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367 (2006), 1328–1334.
27. 27 Kampmann, B, Whittaker, E, Williams, A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 33 (2009), 1374–1382.
28. 28 Tsolia, MN, Mavrikou, M, Critselis, E, et al. Whole blood interferon-γ release assay is a useful tool for the diagnosis of tuberculosis infection particularly among Bacille Calmette Guèrin-vaccinated children. Pediatr Infect Dis J 29 (2010), 1137–1140.
29. 29 Rose, MV, Kimaro, G, Nissen, TN, et al. QuantiFERON®-TB gold in-tube performance for diagnosing active tuberculosis in children and adults in a high burden setting. PLoS One, 7, 2012, e37851.
30. 30 Verhagen, LM, Maes, M, Villalba, JA, et al. Agreement between QuantiFERON®-TB Gold In-Tube and the tuberculin skin test and predictors of positive test results in Warao Amerindian pediatric tuberculosis contacts. BMC Infect Dis, 14, 2014, 383.
31. 31 Chiappini, E, Bonsignori, F, Mazzantini, R, et al. Interferon-gamma release assay sensitivity in children younger than 5 years is insufficient to replace the use of tuberculin skin test in western countries. Pediatr Infect Dis J 33 (2014), 1291–1293.
32. 32 Garazzino, S, Galli, L, Chiappini, E, et al. Performance of interferon-γ release assay for the diagnosis of active or latent tuberculosis in children in the first 2 years of age: a multicenter study of the Italian Society of Pediatric Infectious Diseases. Pediatr Infect Dis J 33 (2014), e226–e231.
33. 33 Bergamini, BM, Losi, M, Vaienti, F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics 123 (2009), e419–e424.
34. 34 Tebruegge, M, de Graaf, H, Sukhtankar, P, et al. Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results. J Clin Microbiol 52 (2014), 2694–2697.
35. 35 Basu Roy, R, Sotgiu, G, Altet-Gomez, N, et al. Identifying predictors of interferon-γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 186 (2012), 378–384.
36. 36 Critselis, E, Amanatidou, V, Syridou, G, et al. The effect of age on whole blood interferon-gamma release assay response among children investigated for latent tuberculosis infection. J Pediatr 161 (2012), 632–638.
37. 37 Zak, DE, Penn-Nicholson, A, Scriba, TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
38. 38 Pai, M, Joshi, R, Dogra, S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 174 (2006), 349–355.
39. 39 Zwerling, A, Benedetti, A, Cojocariu, M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability?. PLoS One, 8, 2013, e54748.
40. 40 Slater, ML, Welland, G, Pai, M, Parsonnet, J, Banaei, N, Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of US healthcare workers. Am J Respir Crit Care Med 188 (2013), 1005–1010.
41. 41 Dorman, SE, Belknap, R, Graviss, EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 189 (2014), 77–87.
42. 42 Shah, M, Kasambira, TS, Adrian, PV, Madhi, SA, Martinson, NA, Dorman, SE, Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS One, 6, 2011, e26787.
43. 43 Middelkoop, K, Mathema, B, Myer, L, et al. Transmission of tuberculosis in a South African community with a high prevalence of HIV infection. J Infect Dis 211 (2015), 53–61.
44. 44 Banaei, N, Gaur, RL, Pai, M, Interferon gamma release assays for latent tuberculosis: what are the sources of variability?. J Clin Microbiol 54 (2016), 845–850.
45. 45 Denkinger, CM, Dheda, K, Pai, M, Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion?. Clin Microbiol Infect 17 (2011), 806–814.